Hernia Repair Devices Market By Product (Hernia Mesh, Fixation Devices, Hernia Patches and Plugs, Biologic and Biosynthetic Grafts); By Application (Inguinal Hernia, Ventral Hernia, Incisional Hernia, Femoral Hernia, Umbilical Hernia, Hiatal and Diaphragmatic Hernia); By End User (Hospitals, Ambulatory Surgery Centers, Specialty Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hernia Repair Devices Market: Procedure Economics Shape Commercial Demand

The Global Hernia Repair Devices Market was valued at USD 5.18 billion in 2025 and is projected to reach USD 7.34 billion by 2032, expanding at a CAGR of 5.1% during 2026–2032, according to Strategic Market Research.

 

Hernia repair devices reinforce weakened abdominal-wall tissue during surgery, with current innovation focused on tissue integration, less traumatic fixation, and absorbable materials. Medtronic’s ProGrip mesh uses self-fixating micro-grips that reduce reliance on tacks, while AbsorbaTack provides temporary absorbable fixation. Symbotex Composite Mesh combines structural reinforcement with a resorbable collagen barrier intended to limit contact with internal organs. B. Braun’s Premilene Mesh Plug is designed to conform to inguinal hernia defects and support tissue ingrowth.

 

Hernia represents a substantial global surgical burden, with an estimated 32.53 million prevalent cases of inguinal, femoral, and abdominal hernias. More than 20 million hernia procedures are performed worldwide each year, including over 1 million repairs annually in the United States. The condition is considerably more common in men than in women. India, China, and Brazil are among the largest contributors to global incidence, reporting approximately 2.45 million, 1.95 million, and 0.71 million new cases, respectively. Together, these three countries account for nearly 39% of incident hernia cases worldwide.These volumes make surgery the principal commercial demand pathway. Prevalence alone overstates the addressable market because only a portion of patients progress from diagnosis or observation to operative repair using a dedicated implant or fixation product.

 

Procedure-Specific Implants Define the Market Boundary

The commercially relevant market includes permanent synthetic mesh, absorbable and biosynthetic mesh, animal-derived grafts, reinforced-tissue matrices, preformed patches and plugs, self-fixating implants, tacks, anchors, straps, and dedicated positioning or deployment systems.

General surgical robots, standard laparoscopic instruments, imaging systems, hospital equipment, nonspecialized sutures, and medicines sit outside the core market. Robotic systems can influence mesh dimensions, fixation, and deployment, but revenue is generated mainly by implants and procedure-linked disposables.

Most U.S. repairs use mesh, according to the FDA, although selected pediatric, small-defect, infected, contaminated, or tissue-repair cases can follow a non-mesh pathway. A procedure therefore creates a purchase opportunity rather than a fixed one-unit sale; complex reconstructions may use larger implants or multiple components.

 

Patient Burden Creates a Multi-Year Surgical Funnel

Approximately 5 million Americans are frequently cited as having an abdominal-wall hernia. Global Burden of Disease analysis estimated 32.53 million prevalent and 13.02 million incident cases of inguinal, femoral, and abdominal hernias in 2019. Prevalent cases increased by 36% between 1990 and 2019, while incident cases rose by almost 64%.

The commercial pathway moves from detection and symptoms to surgical fitness, access to care, operative selection, and final device choice. FDA guidance indicates that 30%–65% of monitored patients may eventually require scheduled surgery, while 3%–5% may need emergency treatment. NIDDK reports that about 70% of men who delay surgery for a minimally symptomatic inguinal hernia undergo repair within five years. This movement from observation to surgery creates deferred demand and separates epidemiological burden from actual device consumption.

A CDC WONDER analysis recorded 2,617 U.S. deaths with hernia as the underlying cause in 2023, while a GBD 2021 analysis estimated 36,877 deaths globally from inguinal, femoral, and abdominal hernias. Mortality remains concentrated in complicated and older-patient cases, but procedure volume is the stronger commercial indicator.

 

Surgery Generates the Core Purchase Event

Medication may control pain or reflux symptoms, but it does not close an abdominal-wall or groin defect. Prehabilitation can improve surgical readiness, while postoperative rehabilitation follows the principal device purchase.

Demand is primarily episodic, with one purchasing event linked to each operation. Repeat demand arises through recurrence, contralateral disease, revision, mesh removal, or a new hernia. A straightforward inguinal repair may use one standardized mesh, whereas complex reconstruction can require a larger implant, multiple segments, separate fixation, or a reinforced-tissue or biosynthetic product. Revenue therefore depends on procedure numbers, implant size, and product mix.

 

Groin Repair Delivers Volume; Complex Repair Supports Higher Value

Inguinal hernia was the largest application in 2025, accounting for 55.0% of revenue, or USD 2,849.0 million. It is projected to reach USD 3,816.8 million by 2032 at a 4.3% CAGR, with its share easing to 52.0% as ventral and incisional repair grow faster. More than 20 million groin-hernia procedures are performed annually, supporting demand for flat synthetic mesh, plugs, preformed systems, self-gripping implants, and fixation devices.

Ventral hernia accounted for 17.0% of the market, or USD 880.6 million, in 2025 and is projected to reach USD 1,394.6 million by 2032 at a 6.8% CAGR, increasing its share to 19.0%. Incisional hernia represented 12.0%, or USD 621.6 million, and is forecast to reach USD 954.2 million at a 6.3% CAGR, raising its share to 13.0%. These defects can be larger, recurrent, irregular, or associated with previous abdominal surgery, obesity, weak tissue, infection risk, and abdominal-wall reconstruction. Such cases can require larger implants, barrier-coated materials, reinforced-tissue matrices, biosynthetic products, positioning systems, or extensive fixation.

Umbilical hernia is expected to maintain a 7.0% share, rising from USD 362.6 million in 2025 to USD 513.8 million in 2032 at a 5.1% CAGR. Hiatal and diaphragmatic hernia is projected to increase from 5.0%, or USD 259.0 million, to 5.5%, or USD 403.7 million, at a 6.5% CAGR as specialist centres adopt purpose-designed reinforcement for selected large or recurrent defects. Femoral hernia remains the smallest application, declining from 4.0% and USD 207.2 million to 3.5% and USD 256.9 million at a 3.1% CAGR because it often uses products and approaches similar to inguinal repair.

A high-volume primary inguinal procedure may use a standardized implant, while a recurrent incisional repair can carry a materially higher device cost. Complex cases also increase the importance of sizing, clinical evidence, surgeon familiarity, and technical support.

 

Minimally Invasive and Robotic Surgery Are Reshaping Product Design

Open repair remains important for routine, emergency, contaminated, and complex cases. Laparoscopic and robotic-assisted procedures create different device requirements because implants must pass through access ports, unfold predictably, maintain orientation, cover the defect, and remain stable during placement.

Robotic adoption is changing mesh geometry, packaging, grip characteristics, deployment methods, and compatible sizing. Products that simplify placement or reduce separate fixation steps can improve procedural efficiency and gain preference among surgeons and hospitals.

In June 2026, Medtronic announced FDA 510(k) clearance for ProGrip Advanced self-gripping polypropylene mesh for robotic-assisted ventral hernia repair. The product is indicated for extraperitoneal reinforcement during laparoscopic or robotic procedures. Medtronic also reported that the wider ProGrip family had been used in more than 6 million procedures cumulatively.

Self-gripping mesh can shift value from separate fixation devices into the implant itself. This may reduce tack consumption in selected procedures while intensifying competition around mesh handling, positioning, fixation strength, and surgeon preference.

 

Material Innovation Is Moving Competition Beyond Permanent Polypropylene

Hernia mesh was the dominant product category in 2025 with a 68.0% share and revenue of USD 3,522.4 million. It is projected to reach USD 4,697.6 million by 2032 at a 4.2% CAGR, although its share is expected to decline to 64.0% as faster-growing fixation and biosynthetic products gain ground. Permanent synthetic mesh remains central because it offers lasting reinforcement, broad availability, and familiar surgical performance.

Fixation devices accounted for 17.0% of revenue, or USD 880.6 million, in 2025 and are forecast to reach USD 1,321.2 million by 2032 at a 6.0% CAGR, increasing their share to 18.0%. Laparoscopic and robotic repairs support demand for absorbable and permanent tackers, powered applicators, suturing systems, and procedure-specific single-use devices.

Hernia patches and plugs represented 9.0% of the market, or USD 466.2 million, in 2025 and are projected to maintain that share, reaching USD 660.6 million by 2032 at a 5.1% CAGR. Pre-shaped patches and combined plug-and-patch systems retain a role in selected inguinal, umbilical, and primary ventral repairs, although surgeon preference is increasingly divided among flat mesh, self-fixating implants, and minimally invasive approaches.

Biologic and biosynthetic grafts are the fastest-growing product category. Their share is projected to rise from 6.0%, or USD 310.8 million, in 2025 to 9.0%, or USD 660.6 million, by 2032 at an 11.4% CAGR. These products are concentrated in complex abdominal-wall reconstruction, recurrent defects, contaminated or potentially contaminated fields, and patients for whom permanent synthetic material may be less desirable.

BD’s Phasix Mesh uses poly-4-hydroxybutyrate as a bioresorbable alternative to permanent mesh, while Phasix ST combines a resorbable scaffold with a temporary hydrogel barrier. Gore’s SYNECOR portfolio includes intraperitoneal and preperitoneal hybrid biomaterials. TELA Bio’s OviTex products combine biologic material with polymer reinforcement, and Cook Medical’s Biodesign portfolio includes animal-derived grafts. These products compete through material duration, handling, evidence, and suitability for defined patient groups.

 

Atraumatic Fixation Is Emerging as a Competitive Battleground

Fixation creates separate disposable revenue through tacks, anchors, straps, and applicators. It can also contribute to tissue trauma and postoperative pain, supporting demand for absorbable fixation, self-gripping mesh, and adhesive-based systems.

TISSIUM’s ECLIPSIUM system uses a biodegradable light-activated adhesive and dedicated delivery tools to secure mesh during laparoscopic ventral hernia repair. The company received an FDA Investigational Device Exemption in 2025 and began clinical evaluation in the United States.

Adhesive and self-fixating systems could reduce demand for penetrating tacks, but adoption will depend on fixation strength, procedural reliability, cost, surgeon training, regulatory progress, and comparative outcomes. These technologies may also shift revenue from multiple disposable fixation units toward higher-value integrated systems.

 

U.S. Demand Reflects Site-of-Care and Reimbursement Economics

Hospitals represented 68.0% of end-user revenue, or USD 3,522.4 million, in 2025 and are projected to reach USD 4,771.0 million by 2032 at a 4.4% CAGR, while their share declines to 65.0%. They remain the principal setting for emergency hernias, recurrent defects, contaminated cases, abdominal-wall reconstruction, and patients requiring comprehensive surgical and postoperative support.

Ambulatory surgery centres accounted for 23.0%, or USD 1,191.4 million, in 2025 and are forecast to become the fastest-growing end-user category, reaching USD 1,908.4 million by 2032 at a 7.0% CAGR and raising their share to 26.0%. Elective inguinal, umbilical, and selected ventral repairs increasingly fit same-day pathways, particularly when minimally invasive techniques and standardized disposable products are used.

Specialty surgical centres are expected to maintain a 9.0% share, increasing from USD 466.2 million to USD 660.6 million at a 5.1% CAGR. Their smaller facility base limits overall share, but high procedure concentration and advanced abdominal-wall reconstruction support meaningful device use per centre.

Ambulatory migration raises attention to operating time, staffing, deployment reliability, discharge predictability, and avoidance of unplanned admission. Medtronic reported nearly 470,000 annual ventral hernia procedures in the United States and noted increasing use of robotic assistance and alternative care sites. Reimbursement is generally linked to the operative episode, requiring hospitals and surgery centres to evaluate implant cost against case complexity, operating-room use, complication exposure, expected outcomes, and payer payment.

 

Global Demand Is Large but Commercial Value Varies by Region

North America held the largest regional share in 2025 at 39.0%, or USD 2,020.2 million. It is projected to reach USD 2,642.4 million by 2032 at a 3.9% CAGR, with its share declining to 36.0%. Mature surgical infrastructure, high mesh utilization, outpatient capacity, and access to advanced fixation and biosynthetic products support the region’s revenue base.

Europe represented 28.0%, or USD 1,450.4 million, in 2025 and is forecast to reach USD 1,981.8 million by 2032 at a 4.6% CAGR, holding 27.0% of the market. Established hernia-surgery volumes and broad availability of synthetic, self-gripping, absorbable, and polymer-based implants sustain regional demand.

Asia Pacific is projected to be the fastest-growing region. Its share is expected to rise from 25.0%, or USD 1,295.0 million, in 2025 to 29.0%, or USD 2,128.6 million, in 2032 at a 7.4% CAGR. Expanding surgical capacity, wider access to laparoscopic procedures, greater diagnosis of abdominal-wall defects, and increasing availability of domestically manufactured meshes support this growth.

Latin America is expected to maintain a 4.5% share, increasing from USD 233.1 million to USD 330.3 million at a 5.1% CAGR. The Middle East and Africa is also projected to retain its share at 3.5%, rising from USD 181.3 million to USD 256.9 million at a 5.1% CAGR. Growth in both regions will remain concentrated in major urban healthcare systems, private hospitals, tertiary medical centres, and expanding surgical networks.

Multinational suppliers therefore operate through two commercial models. Higher-value markets reward differentiated materials, clinical evidence, training, and procedural support. Broader international markets place greater weight on price, tender participation, distribution reach, registration, and reliable supply.

 

Competitive Positioning Depends on Portfolio Breadth and Evidence

BD competes through permanent, absorbable, biosynthetic, barrier-coated, and positioning-system products, including Phasix and Ventralight. Medtronic supplies synthetic, composite, self-fixating, and absorbable fixation products, with recent investment in robotic-compatible repair.

Johnson & Johnson MedTech/Ethicon maintains polypropylene, partially absorbable, composite, patch, plug, and fixation products, including PROLENE, ULTRAPRO, PROCEED, and SECURESTRAP. Gore competes through hybrid biomaterials for intraperitoneal and preperitoneal repair. TELA Bio focuses on reinforced-tissue matrices and biosynthetic soft-tissue products. Cook Medical supplies biologic grafts, while B. Braun participates through polypropylene mesh and preformed plug products such as Premilene Mesh Plug.

TELA Bio reported full-year 2025 revenue of USD 80.3 million, up 16% from 2024. The company also stated that a shift toward smaller hernia-product units reduced average selling prices, showing how implant size and procedure mix can influence revenue even when unit demand remains active.

Competition is shaped by portfolio breadth, surgeon familiarity, evidence, contracting, distribution, and support for open, laparoscopic, and robotic workflows. Diversified suppliers benefit from established hospital relationships, while focused companies compete through material differentiation.

 

Safety Surveillance Raises the Value of Clinical Evidence

Surgeons and procurement teams consider infection, chronic pain, adhesion, obstruction, mesh migration, contraction, seroma, fistula, reoperation, and removal risk alongside recurrence prevention.

The FDA has reviewed more than 55,000 adverse-event reports containing hernia-mesh-related terms over a 22-year period. Frequently reported problems included pain, injury, infection, adhesions, inflammation, and additional surgery.

Safety scrutiny increases the value of long-term evidence, post-market surveillance, traceability, patient selection, and accurate labelling. Hospitals increasingly require a clear clinical reason for choosing a premium implant.

 

Market Outlook

The hernia repair devices market will remain closely tied to operative activity rather than prescription volume or total prevalence. Groin repair provides the largest procedure base, while ventral, incisional, recurrent, and complex abdominal-wall repair supports demand for larger and more differentiated implants.

Growth will be supported by the conversion of monitored patients to surgery, treatment of recurrent and complex defects, expansion of ambulatory care, robotic-compatible mesh, resorbable and hybrid materials, and fixation approaches designed to reduce procedural trauma. Product-cost scrutiny, suture-only repair in selected cases, uneven surgical access, safety concerns, and litigation exposure will limit unrestricted adoption.

 

Hernia Repair Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.18 Billion
Revenue Forecast in 2032	USD 7.34 Billion
Overall Growth Rate	CAGR of 5.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Hernia Mesh, Fixation Devices, Hernia Patches and Plugs, Biologic and Biosynthetic Grafts
By Application	Inguinal Hernia, Ventral Hernia, Incisional Hernia, Femoral Hernia, Umbilical Hernia, Hiatal and Diaphragmatic Hernia
By End User	Hospitals, Ambulatory Surgery Centers, Specialty Surgical Centers
By Region	North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of hernia disorders, increasing adoption of minimally invasive surgical procedures, growing demand for advanced mesh technologies, and expansion of ambulatory surgical care facilities
Customization Option	Available upon request